ORENCIA is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by E.r. Squibb & Sons, L.l.c.. The primary component is Abatacept.
Product ID | 0003-2187_1965849a-8f1d-4015-a434-68f02c6d43c3 |
NDC | 0003-2187 |
Product Type | Human Prescription Drug |
Proprietary Name | ORENCIA |
Generic Name | Abatacept |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2009-01-01 |
Marketing Category | BLA / BLA |
Application Number | BLA125118 |
Labeler Name | E.R. Squibb & Sons, L.L.C. |
Substance Name | ABATACEPT |
Active Ingredient Strength | 250 mg/15mL |
Pharm Classes | Decreased Cytokine Activity [PE], Recombinant Fusion Proteins [CS], Selective T Cell Costimulation Modulator [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2009-01-01 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA125118 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2009-01-01 |
Marketing Category | BLA |
Application Number | BLA125118 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2009-01-01 |
Ingredient | Strength |
---|---|
ABATACEPT | 250 mg/15mL |
SPL SET ID: | 0836c6ac-ee37-5640-2fed-a3185a0b16eb |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0003-2187 | ORENCIA | abatacept |
0003-2188 | ORENCIA | abatacept |
0003-2814 | ORENCIA | abatacept |
0003-2818 | ORENCIA | abatacept |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ORENCIA 78756090 3184992 Live/Registered |
Bristol-Myers Squibb Company 2005-11-17 |
ORENCIA 78465053 not registered Dead/Abandoned |
Bristol-Myers Squibb Company 2004-08-10 |
ORENCIA 76213107 2948497 Live/Registered |
BRISTOL-MYERS SQUIBB COMPANY 2001-02-20 |